Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablets in Healthy Adults
NCT06522763Phase 1Not yet recruiting
- Sponsor
- Swiss Pharma
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sulfadoxine + pyrimethamine in malaria (2 arms), sponsored by Swiss Pharma. Primary endpoints: Maximal Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve at 72 hours. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sulfadoxine + pyrimethamine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06522763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522763.